UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Translation control of the immune checkpoint in cancer and its therapeutic targeting

Nature medicine, 2019-02, Vol.25 (2), p.301-311

2019

Volltextzugriff (PDF)

Nociceptor Translational Profiling Reveals the Ragulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain

The Journal of neuroscience, 2019-01, Vol.39 (3), p.393-411

2019

Volltextzugriff (PDF)

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Journal of medicinal chemistry, 2020-06, Vol.63 (11), p.5879-5955

2020

Volltextzugriff (PDF)

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

Frontiers in oncology, 2021-11, Vol.11, p.766298-766298

2021

Volltextzugriff (PDF)

Targeting mutant KRAS

Current opinion in chemical biology, 2021-06, Vol.62, p.101-108

2021

Volltextzugriff (PDF)

mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation

JCI insight, 2021-06, Vol.6 (11)

2021

Volltextzugriff (PDF)

Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

Journal of medicinal chemistry, 2002-08, Vol.45 (18), p.3905-3927

2002

Volltextzugriff (PDF)

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.26-36

2021

Volltextzugriff (PDF)

A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice

Neurotherapeutics, 2021-01, Vol.18 (1), p.624-639

2021

Volltextzugriff (PDF)

p53 is associated with cellular microtubules and is transported to the nucleus by dynein

Nature cell biology, 2000-10, Vol.2 (10), p.709-717

2000

Volltextzugriff (PDF)

Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease

The American journal of pathology, 1997-06, Vol.150 (6), p.1933-1939

1997

Volltextzugriff (PDF)

Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effects

Journal of medicinal chemistry, 2000-11, Vol.43 (22), p.4126-4134

2000

Volltextzugriff (PDF)

1H-pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: Highly potent 2,6-difluorophenacyl analogues

Bioorganic & medicinal chemistry letters, 2003-07, Vol.13 (14), p.2405-2408

2003

Volltextzugriff (PDF)

1H-pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases

Bioorganic & medicinal chemistry letters, 2003-03, Vol.13 (6), p.1133-1136

2003

Volltextzugriff (PDF)

Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5948-5948

2024

Volltextzugriff (PDF)

Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases

Bioorganic & medicinal chemistry letters, 2004-06, Vol.14 (11), p.2973-2977

2004

Volltextzugriff (PDF)

Therapeutic Potential of Targeting the Cell Cycle

Chemical research in toxicology, 2000-10, Vol.13 (10), p.940-943

Webster, Kevin R

2000

Volltextzugriff (PDF)

The therapeutic potential of targeting the cell cycle

Expert opinion on investigational drugs, 1998-06, Vol.7 (6), p.865-887

Webster, Kevin R

1998

Volltextzugriff (PDF)

Abstract 4142: Physical and functional interactions between MNK and mTOR signaling regulate the activation and differentiation of T cells

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4142-4142

2019

Volltextzugriff (PDF)

Abstract 4343: A focused CRISPR screen to identify synthetic lethal interactions with the novel eIF4A inhibitor eFT226 in KRAS driven NSCLC

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4343-4343

2019

Volltextzugriff (PDF)

Identification of CDK4 Sequences Involved in Cyclin D1 and p16 Binding

The Journal of biological chemistry, 1997-07, Vol.272 (30), p.18869-18874

1997

Volltextzugriff (PDF)

Abstract 1955: Inhibition of eIF4A by eFT226 blocks KRAS mutant tumor growth

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1955-1955

2020

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(255)
Mit Volltextzugriff
(236)

Publikationsform

Sprache

Englisch
(271)
Japanisch
(51)

Erscheinungsjahr

n.n

Thema

Science & Technology
(170)
Life Sciences & Biomedicine
(140)
Humans
(95)
Animals
(49)
Biological And Medical Sciences
(45)
Male
(35)
Female
(34)
Pharmacology & Pharmacy
(32)
Physical Sciences
(28)
Adult
(27)
Chemistry, Medicinal
(27)
Medical Sciences
(27)
Mice
(26)
Fundamental And Applied Biological Sciences. Psychology
(23)
Biochemistry & Molecular Biology
(19)
Chemistry
(17)
Multidisciplinary Sciences
(17)
Science & Technology - Other Topics
(17)
Enzyme Inhibitors - Pharmacology
(15)
General & Internal Medicine
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Translation control of the immune checkpoint in cancer and its therapeutic targeting

Nociceptor Translational Profiling Reveals the Ragulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

Targeting mutant KRAS

mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation

Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice

p53 is associated with cellular microtubules and is transported to the nucleus by dynein

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease

Correction to N‑(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N‑[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effects

1H-pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: Highly potent 2,6-difluorophenacyl analogues

1H-pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases

Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance

Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases

Therapeutic Potential of Targeting the Cell Cycle

The therapeutic potential of targeting the cell cycle

Abstract 4142: Physical and functional interactions between MNK and mTOR signaling regulate the activation and differentiation of T cells

Abstract 4343: A focused CRISPR screen to identify synthetic lethal interactions with the novel eIF4A inhibitor eFT226 in KRAS driven NSCLC

Identification of CDK4 Sequences Involved in Cyclin D1 and p16 Binding

Abstract 1955: Inhibition of eIF4A by eFT226 blocks KRAS mutant tumor growth

Suchergebnisse filtern